Table 1.
Scheme for experimental design in murine allergy model
| Exp # | # Mice, strain | Treatment before and/or after OVA immunization | Harvest | ||
| 1 | 16 NIH/OlaHsd | AndoSan™ or PBS p.o.* (200 μl) ↓ |
serum, spleen ↑ |
||
| 2 | 16 NIH/OlaHsd | AndoSan™/PBS p.o. ↓ |
serum, spleen ↑ |
||
| 3 | 8 C57Bl/6 | AndoSan™/PBS p.o. and/or ↓ |
AndoSan™/PBS p.o. ↓ |
serum, spleen ↑ |
|
| 4 | 8 Balb/c | AndoSan™/PBS s.c. in foot pad (20 μl)** ↓ |
serum, PLN ↑ |
||
| Day | -1 | 0 | 19, | 20 | 26 |
| Immunization | ↑ OVA (10 μg) + Al(OH)3 s.c. in tailbase or foot pad + |
↑ OVA s.c |
↑ Sacrifice |
||
*200 μl of AndoSan™ or PBS was given p.o. via a gastric catheter. ** OVA and Al(OH)3 (2 mg) was dissolved in AndoSan™ or PBS before s.c. injection in foot pad.